RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by EpicentRx, Inc., active and no longer recruiting.
Overview
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer is a phase 2 interventional study registered as NCT05966194 by EpicentRx, Inc., with 216 participants enrolled, started 2024-04-02 and due to reach its primary completion in 2027-07-01. Interventions recorded: RRx-001, Intensity Modulated Radiation Therapy (IMRT) and Cisplatin for injection 100 mg/m2.
Similar pages
not linked directly; found by shared links- TrialA Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
- TrialA Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Shares EpicentRx and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Shares Cisplatin, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialEfficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
Shares Cisplatin, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Cisplatin, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.